New study data points to St. Jude’s Dorsal Root Ganglion stimulator delivering better pain relief than traditional spinal cord stimulation.
St Jude
CE Mark for St. Jude’s “Industry First” Neuromodulation Trial System
St. Jude Medical, Inc., has gained CE Mark approval and announced the European launch of its Invisible Trial System, an app-based and wireless neuromodulation programming system leveraging Apple™ iPod touch™ and iPad mini™ technology.
Good Press for St. Jude Medical’s Quadripolar Technology at HRS 2015
Presentations at this year’s HRS event point to improved clinical outcomes, increased survival and better cost utilization with the SJM™ Quadra CRT system
EU Nod for St. Jude’s ICD MRI-Compatibility Claim
MRI-conditionality is rapidly becoming industry standard, at least in St. Jude’s range, as more ICD products are approved to make this claim in Europe
St. Jude Medical Completes Acquisition of Spinal Modulation, Inc.
Try Turns to Buy as St. Jude slots Spinal Modulation’s Axium into its chronic pain portfolio
U.S. Study of Smallest Pediatric Mechanical Heart Valve Starts
St. Jude Medical, Inc. has launched the HALO U.S. IDE Trial, designed to evaluate the safety and efficacy of the smallest pediatric mechanical heart valve in the world
FDA Approves First Flexible-Tipped Cardiac Ablation Catheter
St. Jude’s FlexAbility is the first flexible tipped ablation device for the treatment of cardiac arrhythmias to gain U.S. approval
St.Jude on the Money in Q4
Preliminary revenue results for St. Jude’s fourth quarter see it expecting to report overall net sales growth with starring performances from Atrial Fibrillation
New Study Will Evaluate Adjunctive Ablation in ICD/CRT-D Ventricular Tachycardia Treatment
St. Jude’s FlexAbility ablation catheter will be used to assess benefits of catheter ablation as an adjunctive therapy for patients at risk for life-threatening arrhythmias.
CE Mark for World’s Only MultiPoint Pacing Pacemaker
Quadra Allure MP™ CRT-P expands the St. Jude Medical heart failure portfolio and is supported by newly presented data that demonstrate an increase in patient response to multipoint pacing therapy
CardioMEMS™ HF Heart Monitoring Significantly Reduced 30-Day Hospital Readmission Rates
A retrospective data analysis from a study into St. Jude’s CardioMEMS™ HF monitoring sensor shows significant a reduction in 30-day hospital readmission rates for patients age 65 and older.
FDA Approval for St. Jude’s TactiCath Quartz Contact Force Ablation Catheter for AF
TactiCath Quartz contact-force technology provides physicians with more control of contact force during ablation procedures in order to create more effective lesions in paroxysmal AF treatment.
St. Jude Pacing Leads Now CE Marked as MRI Friendly
St. Jude Medical, Inc. has gained CE Mark approval that will allow patients fitted with its Tendril™ STS and IsoFlex™ Optim™ pacing leads, to undergo MRI scans.
Tangled Web Sees ICD Inventor Awarded $309 Million for now
The family of the man who helped invent the ICD has been awarded $309 million against Boston Scientific, although appeals loom.
Study Confirms Fractional Flow Reserve Measurement Drives NSTEMI Treatment Strategy
Newly presented data says that using FFR measurement technology changed the course of treatment for more than one fifth of patients suffering non-ST segment elevation myocardial infarction (NSTEMI) heart attacks.
Comparative Study Supports St. Jude Quadripolar Leads vs Bipolar
St. Jude claims its Quadripolar pacing system set the standard and a newly presented study is a strong addition to the more than 100 publications supporting the argument.